Skip to main content
Roger Gomis

Roger Gomis

Institut de Recerca Biomèdica

Life & Medical Sciences

Dr. Roger Gomis is an ICREA Research Professor and a member of the Oncology Program at the Institute for Research in Biomedicine, Barcelona. He received his PhD in biochemistry from the University of Barcelona in 2002, and was a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center in Prof. Joan Massagué's laboratory. In 2007, he assumed his current position. Since 2018 he is an associate professor at the University of Barcelona. Dr. Roger Gomis is interested in how growth factors, signaling pathways, and gene expression programs control normal cell behavior and cancer cell metastasis. Driven by the problem of metastasis, which is the cause of 90% of cancer deaths, his laboratory is pursuing the molecular and genetic mechanisms of metastasis. In particular, identifying  genes that enable cancer to metastasize clinically relevant sites. In 2012 Roger founded Inbiomotion as an ICREA and IRB Barcelona spin-off company from his research. 

Research interests

Although metastasis is the leading cause of cancer death, we are still ill-prepared to fight it. Chemotherapy targets high-proliferating rather than the low-proliferating metastatic cells—allowing these to spread from the primary tumor to distant sites, where they resist conventional treatments, proliferate, and cause vital organ failure. We and others have helped to simplify our understanding of metastasis as an orderly sequence of basic steps, which allows us to rationalize the biological properties required for metastatic disease. We know that cancer cells must orchestrate diverse cellular functions to overcome the difficulties of transiting into the metastatic cascade; these functions are highly dependent on the interactions between the metastatic cell, the tumor, and host stroma. We now need a better understanding of steps of the kinetics and mechanisms that regulate tissue-specific metastasis progression, as a prerequisite for developing effective therapies in the future.

Selected publications

– Tarrago-Celada, Josep; Foguet, Carles; Tarrado-Castellarnau, Miriam; Marin, Silvia; Hernandez-Alias, Xavier; Perarnau, Jordi; Morrish, Fionnuala; Hockenbery, David; Gomis, Roger R.; Ruppin, Eytan; Yuneva, Mariia; de Atauri, Pedro; Cascante, Marta 2021, ‘Cysteine and Folate Metabolism Are Targetable Vulnerabilities of Metastatic Colorectal Cancer’, Cancers, 13, 3, 425.

– Nunez-Olle M, Guiu M & Gomis RR 2021. ‘In Vivo Assessment of Metastatic Cell Potential in Prostate Cancer.’ Methods Mol Biol. 2294:253-267.

– Paterson AHG, Lucas PC, Anderson SJ, Mamounas EP, Brufsky A, Baez-Diaz L, King KM, Lad T, Robidoux A, Finnigan M, Sampayo M, Tercero JC, Mairet JJ, Wolff AC, Fehrenbacher L, Wolmark N, Gomis RR. 2021. ‘MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice’. JNCI Cancer Spectr. ;5(4):pkab054.

– Olivan M, Garcia M, Suárez L, Guiu M, Gros L, Méndez O, Rigau M, Reventós J, Segura MF, de Torres I et al, 2021, ‘Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples’. Cancers 13, 24, 6202.

Selected research activities

Co-Organizer 2021 Evolution in metastasis symposium. EVOMET Conference, Barcelona

Chairman of the PhD Program Committee/ IRB Barcelona / Spain

Chair of the Cancer Study Section of the Spanish Government Agency for the Evaluation of Research

Coordinator of Deconstructing the evolution of metastasis EU H2020-MSCA-ITN-2020


ICREA Memoir 2021